Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 5/2012

Open Access 01-10-2012 | Research article

Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis

Authors: Qin Shi, Jamilah Abusarah, Ghayath Baroudi, Julio C Fernandes, Hassan Fahmi, Mohamed Benderdour

Published in: Arthritis Research & Therapy | Issue 5/2012

Login to get access

Abstract

Introduction

Recent studies revealed that co-morbidity and mortality due to cardiovascular disease are increased in patients with rheumatoid arthritis (RA) but little is known about factors involved in these manifestations. This study aimed at characterizing the impact of arthritis on oxidative stress status and tissue fibrosis in the heart of rats with adjuvant-induced arthritis (AIA).

Methods

AIA was induced with complete Freund's adjuvant in female Lewis rats. Animals were treated by oral administration of vehicle or angiotensin-converting enzyme inhibitor ramipril (10 mg/kg/day) for 28 days, beginning 1 day after arthritis induction. Isolated adult cardiomyocytes were exposed to 10 μM 4-hydroxynonenal (HNE) for 24 hours in the presence or absence of 10 μM ramipril.

Results

Compared to controls, AIA rats showed significant 55 and 30% increase of 4-HNE/protein adducts in serum and left ventricular (LV) tissues, respectively. Cardiac mitochondrial NADP+-isocitrate dehydrogenase (mNADP-ICDH) activity decreased by 25% in AIA rats without any changes in its protein and mRNA expression. The loss of mNADP-ICDH activity was correlated with enhanced accumulation of HNE/mNADP-ICDH adducts as well as with decrease of glutathione and NADPH. Angiotensin II type 1 receptor (AT1R) expression and tissue fibrosis were induced in LV tissues from AIA rats. In isolated cardiomyocytes, HNE significantly decreased mNADP-ICDH activity and enhanced type I collagen and connective tissue growth factor expression. The oral administration of ramipril significantly reduced HNE and AT1R levels and restored mNADP-ICDH activity and redox status in LV tissues of AIA rats. The protective effects of this drug were also evident from the decrease in arthritis scoring and inflammatory markers.

Conclusion

Collectively, our findings disclosed that AIA induced oxidative stress and fibrosis in the heart. The fact that ramipril attenuates inflammation, oxidative stress and tissue fibrosis may provide a novel strategy to prevent heart diseases in RA.
Appendix
Available only for authorised users
Literature
1.
Williams RO, Feldmann M, Maini RN: Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha. Ann Rheum Dis. 2000, 59: i75-i80. 10.1136/ard.59.suppl_1.i75.PubMedCentralCrossRefPubMed
2.
Choi EM: Oxidative status of DBA/1J mice with type II collagen-induced arthritis. J Appl Toxicol. 2007, 27: 472-481. 10.1002/jat.1228.CrossRefPubMed
3.
Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC: Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003, 107: 1303-1307. 10.1161/01.CIR.0000054612.26458.B2.CrossRefPubMed
4.
Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE: Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005, 52: 722-732. 10.1002/art.20878.CrossRefPubMed
5.
Libby P: Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006, 83: 456S-460S.PubMed
6.
Rudominer RL, Roman MJ, Devereux RB, Paget SA, Schwartz JE, Lockshin MD, Crow MK, Sammaritano L, Levine DM, Salmon JE: Independent association of rheumatoid arthritis with increased left ventricular mass but not with reduced ejection fraction. Arthritis Rheum. 2009, 60: 22-29. 10.1002/art.24148.PubMedCentralCrossRefPubMed
7.
Drazner MH, Rame JE, Marino EK, Gottdiener JS, Kitzman DW, Gardin JM, Manolio TA, Dries DL, Siscovick DS: Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol. 2004, 43: 2207-2215. 10.1016/j.jacc.2003.11.064.CrossRefPubMed
8.
Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Kunzler P, Enseleit F, Periat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F: Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008, 117: 2262-2269. 10.1161/CIRCULATIONAHA.107.734384.CrossRefPubMed
9.
de Jong HJ, Vandebriel RJ, Saldi SR, van DL, van LH, Cohen Tervaert JW, Klungel OH: Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the risk of developing rheumatoid arthritis in antihypertensive drug users. Pharmacoepidemiol Drug Saf. 2012, 21: 835-43. 10.1002/pds.3291.CrossRefPubMed
10.
Gutteridge JM, Halliwell B: Free radicals and antioxidants in the year 2000. A historical look to the future. Ann N Y Acad Sci. 2000, 899: 136-147.CrossRefPubMed
11.
Leitinger N: Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003, 14: 421-430. 10.1097/00041433-200310000-00002.CrossRefPubMed
12.
Uchida K: Role of reactive aldehyde in cardiovascular diseases. Free Radic Biol Med. 2000, 28: 1685-1696. 10.1016/S0891-5849(00)00226-4.CrossRefPubMed
13.
Kalpakcioglu B, Senel K: The interrelation of glutathione reductase, catalase, glutathione peroxidase, superoxide dismutase, and glucose-6-phosphate in the pathogenesis of rheumatoid arthritis. Clin Rheumatol. 2008, 27: 141-145. 10.1007/s10067-007-0746-3.CrossRefPubMed
14.
15.
Lemarechal H, Allanore Y, Chenevier-Gobeaux C, Ekindjian OG, Kahan A, Borderie D: High redox thioredoxin but low thioredoxin reductase activities in the serum of patients with rheumatoid arthritis. Clin Chim Acta. 2006, 367: 156-161. 10.1016/j.cca.2005.12.006.CrossRefPubMed
16.
Ku IA, Imboden JB, Hsue PY, Ganz P: Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J. 2009, 73: 977-985. 10.1253/circj.CJ-09-0274.CrossRefPubMed
17.
Rho YH, Chung CP, Oeser A, Solus JF, Gebretsadik T, Shintani A, Raggi P, Milne GL, Stein CM: Interaction between oxidative stress and high-density lipoprotein cholesterol is associated with severity of coronary artery calcification in rheumatoid arthritis. Arthritis Care Res. 2010, 62: 1473-1480. 10.1002/acr.20237.CrossRef
18.
Khan F, Siddiqui AA: Prevalence of anti-3-nitrotyrosine antibodies in the joint synovial fluid of patients with rheumatoid arthritis, osteoarthritis and systemic lupus erythematosus. Clin Chim Acta. 2006, 370: 100-107. 10.1016/j.cca.2006.01.020.CrossRefPubMed
19.
Leitinger N: The role of phospholipid oxidation products in inflammatory and autoimmune diseases: evidence from animal models and in humans. Subcell Biochem. 2008, 49: 325-350. 10.1007/978-1-4020-8830-8_12.CrossRefPubMed
20.
Zarkovic N: 4-hydroxynonenal as a bioactive marker of pathophysiological processes. Mol Aspects Med. 2003, 24: 281-291. 10.1016/S0098-2997(03)00023-2.CrossRefPubMed
21.
Esterbauer H, Schaur RJ, Zollner H: Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med. 1991, 11: 81-128. 10.1016/0891-5849(91)90192-6.CrossRefPubMed
22.
Awasthi YC, Sharma R, Cheng JZ, Yang Y, Sharma A, Singhal SS, Awasthi S: Role of 4-hydroxynonenal in stress-mediated apoptosis signaling. Mol Aspects Med. 2003, 24: 219-230. 10.1016/S0098-2997(03)00017-7.CrossRefPubMed
23.
Poli G, Schaur RJ: 4-Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life. 2000, 50: 315-321. 10.1080/15216540051081092.CrossRefPubMed
24.
Fernandes JC, Wang H, Jreyssaty C, Benderdour M, Lavigne P, Qiu X, Winnik FM, Zhang X, Dai K, Shi Q: Bone-protective effects of nonviral gene therapy with folate-chitosan DNA nanoparticle containing interleukin-1 receptor antagonist gene in rats with adjuvant-induced arthritis. Mol Ther. 2008, 16: 1243-1251. 10.1038/mt.2008.99.CrossRefPubMed
25.
Vaillancourt F, Silva P, Shi Q, Fahmi H, Fernandes JC, Benderdour M: Elucidation of molecular mechanisms underlying the protective effects of thymoquinone against rheumatoid arthritis. J Cell Biochem. 2011, 112: 107-117. 10.1002/jcb.22884.CrossRefPubMed
26.
Morquette B, Shi Q, Lavigne P, Ranger P, Fernandes JC, Benderdour M: Production of lipid peroxidation products in osteoarthritic tissues: new evidence linking 4-hydroxynonenal to cartilage degradation. Arthritis Rheum. 2006, 54: 271-281. 10.1002/art.21559.CrossRefPubMed
27.
Benderdour M, Charron G, Deblois D, Comte B, Des Rosiers C: Cardiac mitochondrial NADP+-isocitrate dehydrogenase is inactivated through 4-hydroxynonenal adduct formation: an event that precedes hypertrophy development. J Biol Chem. 2003, 278: 45154-45159. 10.1074/jbc.M306285200.CrossRefPubMed
28.
Chen SH, Fahmi H, Shi Q, Benderdour M: Regulation of microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase-activating protein/5-lipoxygenase by 4-hydroxynonenal in human osteoarthritic chondrocytes. Arthritis Res Ther. 2010, 12: R21-10.1186/ar2926.PubMedCentralCrossRefPubMed
29.
Whittaker P, Kloner RA, Boughner DR, Pickering JG: Quantitative assessment of myocardial collagen with picrosirius red staining and circularly polarized light. Basic Res Cardiol. 1994, 89: 397-410. 10.1007/BF00788278.CrossRefPubMed
30.
Hawat G, Benderdour M, Rousseau G, Baroudi G: Connexin 43 mimetic peptide Gap26 confers protection to intact heart against myocardial ischemia injury. Pflugers Arch. 2010, 460: 583-592. 10.1007/s00424-010-0849-6.CrossRefPubMed
31.
Murakami K, Haneda M, Makino T, Yoshino M: Protective effect of NADP-isocitrate dehydrogenase on the paraquat-mediated oxidative inactivation of aconitase in heart mitochondria. Environ Toxicol Pharmacol. 2006, 22: 148-152. 10.1016/j.etap.2006.02.001.CrossRefPubMed
32.
Le Corvoisier P, Adamy C, Sambin L, Crozatier B, Berdeaux A, Michel JB, Hittinger L, Su J: The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice. Eur J Heart Fail. 2010, 12: 1171-1178. 10.1093/eurjhf/hfq146.PubMedCentralCrossRefPubMed
33.
Bendele AM, Chlipala ES, Scherrer J, Frazier J, Sennello G, Rich WJ, Edwards CK: Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum. 2000, 43: 2648-2659. 10.1002/1529-0131(200012)43:12<2648::AID-ANR4>3.0.CO;2-M.CrossRefPubMed
34.
Bingham CO: The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation. J Rheumatol Suppl. 2002, 65: 3-9.PubMed
35.
Haruna Y, Morita Y, Komai N, Yada T, Sakuta T, Tomita N, Fox DA, Kashihara N: Endothelial dysfunction in rat adjuvant-induced arthritis: vascular superoxide production by NAD(P)H oxidase and uncoupled endothelial nitric oxide synthase. Arthritis Rheum. 2006, 54: 1847-1855. 10.1002/art.21891.CrossRefPubMed
36.
Chen CH, Budas GR, Churchill EN, Disatnik MH, Hurley TD, Mochly-Rosen D: Activation of aldehyde dehydrogenase-2 reduces ischemic damage to the heart. Science. 2008, 321: 1493-1495. 10.1126/science.1158554.PubMedCentralCrossRefPubMed
37.
Lucas DT, Szweda LI: Declines in mitochondrial respiration during cardiac reperfusion: age-dependent inactivation of alpha-ketoglutarate dehydrogenase. Proc Natl Acad Sci USA. 1999, 96: 6689-6693. 10.1073/pnas.96.12.6689.PubMedCentralCrossRefPubMed
38.
Lashin OM, Szweda PA, Szweda LI, Romani AM: Decreased complex II respiration and HNE-modified SDH subunit in diabetic heart. Free Radic Biol Med. 2006, 40: 886-896. 10.1016/j.freeradbiomed.2005.10.040.CrossRefPubMed
39.
Poli G, Schaur RJ, Siems WG, Leonarduzzi G: 4-Hydroxynonenal: A membrane lipid oxidation product of medicinal interest. Med Res Rev. 2008, 28: 569-631. 10.1002/med.20117.CrossRefPubMed
40.
Irwin WA, Gaspers LD, Thomas JA: Inhibition of the mitochondrial permeability transition by aldehydes. Biochem Biophys Res Commun. 2002, 291: 215-219. 10.1006/bbrc.2002.6457.CrossRefPubMed
41.
Scolletta S, Biagioli B: Energetic myocardial metabolism and oxidative stress: let's make them our friends in the fight against heart failure. Biomed Pharmacother. 2010, 64: 203-207. 10.1016/j.biopha.2009.10.002.CrossRefPubMed
42.
Yang Y, Sharma R, Sharma A, Awasthi S, Awasthi YC: Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol. 2003, 50: 319-336.PubMed
43.
Lee JH, Yang ES, Park JW: Inactivation of NADP+-dependent isocitrate dehydrogenase by peroxynitrite. Implications for cytotoxicity and alcohol-induced liver injury. J Biol Chem. 2003, 278: 51360-51371. 10.1074/jbc.M302332200.CrossRefPubMed
44.
Davis JM, Knutson KL, Strausbauch MA, Crowson CS, Therneau TM, Wettstein PJ, Roger VL, Matteson EL, Gabriel SE: A signature of aberrant immune responsiveness identifies myocardial dysfunction in rheumatoid arthritis. Arthritis Rheum. 2011, 63: 1497-1506.PubMedCentralCrossRefPubMed
45.
Giles JT, Fernandes V, Lima JA, Bathon JM: Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. Arthritis Res Ther. 2005, 7: 195-207. 10.1186/ar1814.PubMedCentralCrossRefPubMed
46.
Porter KE, Turner NA: Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009, 123: 255-278. 10.1016/j.pharmthera.2009.05.002.CrossRefPubMed
47.
Camelliti P, Borg TK, Kohl P: Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res. 2005, 65: 40-51. 10.1016/j.cardiores.2004.08.020.CrossRefPubMed
48.
Zhang W, Chancey AL, Tzeng HP, Zhou Z, Lavine KJ, Gao F, Sivasubramanian N, Barger PM, Mann DL: The development of myocardial fibrosis in transgenic mice with targeted overexpression of tumor necrosis factor requires mast cell-fibroblast interactions. Circulation. 2011, 124: 2106-2116. 10.1161/CIRCULATIONAHA.111.052399.PubMedCentralCrossRefPubMed
49.
Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP, Lan HY: C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010, 55: 953-960. 10.1161/HYPERTENSIONAHA.109.140608.CrossRefPubMed
50.
Chiarpotto E, Castello L, Leonarduzzi G, Biasi AF, Poli G: Role of 4-hydroxy-2,3-nonenal in the pathogenesis of fibrosis. Biofactors. 2005, 24: 229-236. 10.1002/biof.5520240127.CrossRefPubMed
51.
Zamara E, Novo E, Marra F, Gentilini A, Romanelli RG, Caligiuri A, Robino G, Tamagno E, Aragno M, Danni O, Autelli R, Colombatto S, Dianzani MU, Pinzani M, Parola M: 4-Hydroxynonenal as a selective pro-fibrogenic stimulus for activated human hepatic stellate cells. J Hepatol. 2004, 40: 60-68.CrossRefPubMed
52.
Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N: Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Arthritis Rheum. 2010, 62: 1319-1328.CrossRefPubMed
53.
Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, Nickenig G: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 2004, 94: 534-541. 10.1161/01.RES.0000115557.25127.8D.CrossRefPubMed
54.
Xu J, Carretero OA, Liu YH, Shesely EG, Yang F, Kapke A, Yang XP: Role of AT2 receptors in the cardioprotective effect of AT1 antagonists in mice. Hypertension. 2002, 40: 244-250. 10.1161/01.HYP.0000029095.23198.AD.CrossRefPubMed
55.
Bunkenburg B, van Amelsvoort T, Rogg H, Wood JM: Receptor-mediated effects of angiotensin II on growth of vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension. 1992, 20: 746-754. 10.1161/01.HYP.20.6.746.CrossRefPubMed
56.
Wollert KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, Drexler H: Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. Circulation. 1997, 95: 1910-1917. 10.1161/01.CIR.95.7.1910.CrossRefPubMed
57.
Zhang C, Hein TW, Wang W, Kuo L: Divergent roles of angiotensin II AT1 and AT2 receptors in modulating coronary microvascular function. Circ Res. 2003, 92: 322-329. 10.1161/01.RES.0000056759.53828.2C.CrossRefPubMed
58.
Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M: Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone. Circulation. 2004, 109: 2213-2220. 10.1161/01.CIR.0000127949.05756.9D.CrossRefPubMed
59.
Marchesi C, Paradis P, Schiffrin EL: Role of the renin-angiotensin system in vascular inflammation. Trends Pharmacol Sci. 2008, 29: 367-374. 10.1016/j.tips.2008.05.003.CrossRefPubMed
60.
Essick EE, Ouchi N, Wilson RM, Ohashi K, Ghobrial J, Shibata R, Pimentel DR, Sam F: Adiponectin mediates cardioprotection in oxidative stress-induced cardiac myocyte remodeling. Am J Physiol Heart Circ Physiol. 2011, 301: H984-H993. 10.1152/ajpheart.00428.2011.PubMedCentralCrossRefPubMed
61.
Zhao W, Ahokas RA, Weber KT, Sun Y: ANG II-induced cardiac molecular and cellular events: role of aldosterone. Am J Physiol Heart Circ Physiol. 2006, 291: H336-H343. 10.1152/ajpheart.01307.2005.CrossRefPubMed
62.
Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002, 283: H1802-H1810.CrossRefPubMed
63.
Tojo A, Onozato ML, Kobayashi N, Goto A, Matsuoka H, Fujita T: Angiotensin II and oxidative stress in Dahl Salt-sensitive rat with heart failure. Hypertension. 2002, 40: 834-839. 10.1161/01.HYP.0000039506.43589.D5.CrossRefPubMed
64.
Tikiz C, Utuk O, Pirildar T, Bayturan O, Bayindir P, Taneli F, Tikiz H, Tuzun C: Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis. J Rheumatol. 2005, 32: 2095-2101.PubMed
65.
Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC: The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford). 2005, 44: 24-31. 10.1093/rheumatology/keh398.CrossRef
Metadata
Title
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis
Authors
Qin Shi
Jamilah Abusarah
Ghayath Baroudi
Julio C Fernandes
Hassan Fahmi
Mohamed Benderdour
Publication date
01-10-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue 5/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar4062

Other articles of this Issue 5/2012

Arthritis Research & Therapy 5/2012 Go to the issue

Research article

Osteogenesis and osteoclast inhibition in rheumatoid arthritis patients treated with bisphosphonates alone or in combination with pitavastatin over an 18-month follow-up after more than 4 years of treatment with bisphosphonates

Review

Common variable immunodeficiency - an update

Research article

Chondrocalcinosis is common in the absence of knee involvement

Research article

Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

Research article

Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study

Research article

Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits